Expanded Access to Venetoclax

Official Title: 
Expanded Access to Venetoclax
Brief Summary: 
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
EA Type
Individual Patients
Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis

Drug: Venetoclax
Venetoclax will be administered orally.
Other Name: ABT-199
Other Name: GDC-0199

Eligibility Criteria: 

Inclusion Criteria:

- The participant must not be eligible for a venetoclax clinical trial.

- Pediatric participants may be evaluated on a case by case basis.

Eligibility Gender: 
Eligibility Age: 
Minimum: 18 Years


AbbVie Inc.
Study Director

EA Number: 
Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme
MeSH Terms: 
Leukemia, Leukemia, Myeloid, Acute, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Amyloidosis, Venetoclax
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about